Medtronic, Inc. : Medtronic Completes Strategic Investment in LifeTech Scientific Corporation

    Medtronic, Inc. : Medtronic Completes Strategic Investment in LifeTech
                            Scientific Corporation

Medtronic, Inc.

        Strategic Alliance to Leverage Best of Both Companies to Reach
         Cardiovascular Patients in China and Other Emerging Markets

MINNEAPOLIS and Shenzhen- January 30, 2013 - Medtronic, Inc. (NYSE:MDT) and
LifeTech Scientific Corporation (8122:HK) today announced the closing of a
transaction creating a strategic alliance thatbrings together the resources
and technologies of the world's largest medical device company with the local
market expertise, brand recognition and growth potential of a recognized
leader in China, which is fast becoming one of the world's largest device
markets. The strategic alliance will allow each company to serve
cardiovascular patients and clinicians who previously have been unreachable by
either company alone, and to develop a more robust cardiovascular platform.

Under the terms of the definitive agreements, Medtronic purchased a 19.0
percent equity interest in LifeTech, and received the right of first
negotiation to distribute current and future LifeTech products as well as the
opportunity to acquire additional ownership in LifeTech. Medtronic will also
provide services and expertise to LifeTech to support its continued growth,
development pipeline and manufacturing capabilities to better serve patients
and clinicians in China and globally.

Medtronic purchased its initial equity investment for HK$3.80 per share or
HK$361 million (approximately US$46.5 million) in total. Medtronic also
purchased a HK$152 million (approximately US$19.6 million) convertible note
representing an additional approximately 7.4 percent equity on a fully-diluted
post-conversion basis. Medtronic will also have the opportunity to acquire
additional convertible notes.The investment is consistent with Medtronic's
capital allocation strategy and meets internal financial return expectations.

The transaction closing follows the receipt of approvals from the shareholders
of LifeTech and applicable Chinese and Hong Kong regulatory authorities.

In collaborating with leading clinicians, researchers and scientists,
Medtronic offers the broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company is continuing its commitment to offering products and
services that deliver clinical and economic value to healthcare consumers and
providers worldwide.

About Medtronic
Medtronic, Inc. (, headquartered in Minneapolis, is the
global leader in medical technology - alleviating pain, restoring health, and
extending life for millions of people around the world.

About LifeTech
LifeTech Scientific Corporation is a public company listed on the Hong Kong
Stock Exchange dedicated to researching, developing, manufacturing and
marketing advanced minimally invasive interventional medical devices for
cardiovascular and peripheral vascular diseases and disorders, with a global
reach and subsidiaries in China, Netherlands, India, Russia and France. As a
leading medical device company in China with roots in healthcare going back 13
years, LifeTech has built up a strong worldwide sales network, offering a
broad range of products to over 30 countries across Asia, Europe, South
America, North America and Africa.

This press release contains forward-looking statements that involve risks and
uncertainties. Such forward-looking statements include expectations regarding
benefits to LifeTech and Medtronic resulting from the strategic alliance. The
statements in this release are based upon current expectations and are subject
to certain risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements, including
risks related to the implementation of the strategic alliance agreements,
risks associated with whether or not Medtronic acquires additional ownership
in LifeTech, difficulties and delays inherent in the development,
manufacturing, marketing and sale of medical products, government regulation,
general economic conditions and other risks and uncertainties set forth in
Medtronic's periodic reports on file with the U.S. Securities and Exchange
Commission, including, but not limited to, Medtronic's Annual Report on Form
10-K for the fiscal year ended April 27, 2012 and LifeTech's filings with the
Hong Kong Stock Exchange. Medtronic disclaims any obligation to update or
revise statements contained in this release based on new information, future
events or otherwise.


Winston Wu
Medtronic Public Relations
+86 21 2032 5888

Jeff Warren
Medtronic Investor Relations

Cathy Zhang
LifeTechPublic Relations
+86 755 8602 6292

Lawson Liu
LifeTechInvestor Relations
+86 755 8602 8988


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Medtronic, Inc. via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.